SWM
CLDX icon

SeaCrest Wealth Management’s Celldex Therapeutics CLDX Stock Holding History

SeaCrest Wealth Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$1K – 2151
2018
Q4 		$1K Hold
200
– – ﹤0.01% 1986
2018
Q3 		$1K Sell
200
-40
-17% -$280 ﹤0.01% 2137
2018
Q2 		$2K Buy
+240
New +$3.21K ﹤0.01% 1987

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SeaCrest Wealth Management's CLDX Position: Q1 2019 in Review

SeaCrest Wealth Management sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 200 shares — an estimated $1K sold.

SeaCrest Wealth Management first reported a position in CLDX in Q2 2018 and held it in 3 quarters. The position peaked at $2K in Q2 2018. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • SeaCrest Wealth Management reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 200 Celldex Therapeutics shares in Q1 2019, an estimated $1K.
  • SeaCrest Wealth Management first reported a position in Celldex Therapeutics in Q2 2018 and held it in 3 quarters.
  • SeaCrest Wealth Management's Celldex Therapeutics position peaked at $2K in Q2 2018.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on SeaCrest Wealth Management's 13F filing for Q1 2019, filed 10 May 2019.